BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11698916)

  • 1. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate.
    Schaller JL; Burkland GA
    MedGenMed; 2001 Sep; 3(5):9. PubMed ID: 11698916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome.
    Payne SM; Kovacs MJ
    Ann Pharmacother; 2004; 38(7-8):1215-8. PubMed ID: 15187212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
    Garg A; Duggal L; Aggarwal S; Jain N
    J Assoc Physicians India; 2006 Nov; 54():883-6. PubMed ID: 17249259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are various Babesia species a missed cause for hypereosinophilia? A follow-up on the first reported case of imatinib mesylate for idiopathic hypereosinophilia.
    Schaller JL; Burkland GA; Langhoff PJ
    MedGenMed; 2007 Feb; 9(1):38. PubMed ID: 17435644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate for the treatment of hypereosinophilic syndromes.
    Antoniu SA
    Curr Opin Investig Drugs; 2006 Nov; 7(11):980-4. PubMed ID: 17117585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition].
    Moles MP; Landry J; Roche-Lestienne C; Godon A; Schmidt-Tanguy A; Gardembas M; Le Clech C; Verret JL; Zandecki M; Blanchet O
    Ann Biol Clin (Paris); 2005; 63(3):317-22. PubMed ID: 15951264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of idiopathic hypereosinophilic syndrome with imatinib].
    Sørensen AL; Larsen H
    Ugeskr Laeger; 2008 Jan; 170(4):254. PubMed ID: 18282461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.
    Hasselbalch HC; Bjerrum OW; Jensen BA; Clausen NT; Hansen PB; Birgens H; Therkildsen MH; Ralfkiaer E
    Am J Hematol; 2003 Dec; 74(4):238-42. PubMed ID: 14635203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reader's response to "Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate".
    Shinkarow JW
    MedGenMed; 2007; 9(1):39. PubMed ID: 17441290
    [No Abstract]   [Full Text] [Related]  

  • 10. Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib.
    Hofmann SC; Technau K; Müller AM; Lübbert M; Bruckner-Tuderman L
    J Am Acad Dermatol; 2007 May; 56(5 Suppl):S68-72. PubMed ID: 17097375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report.
    Tan D; Hwang W; Ng HJ; Goh YT; Tan P
    Int J Hematol; 2004 Jul; 80(1):75-7. PubMed ID: 15293573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical management of the hypereosinophilic syndromes.
    Cogan E; Roufosse F
    Expert Rev Hematol; 2012 Jun; 5(3):275-89; quiz 290. PubMed ID: 22780208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome and severe heart involvement.
    Anghel G; De Rosa L; Ruscio C; Petti N; Riccardi M; Severino A; Majolino I
    Tumori; 2005; 91(1):67-70. PubMed ID: 15850007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective treatment of hypereosinophilic syndrome with imatinib mesylate.
    Salem Z; Zalloua PA; Chehal A; Bitar N; Abboud M; Kadri A; Chami B; Bazarbachi A
    Hematol J; 2003; 4(6):410-2. PubMed ID: 14671612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
    Warren E; Ward S; Gordois A; Scuffham P
    Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.
    Ault P; Cortes J; Koller C; Kaled ES; Kantarjian H
    Leuk Res; 2002 Sep; 26(9):881-4. PubMed ID: 12127565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5.
    Mehr S; Rego S; Kakakios A; Kilham H; Kemp A
    J Pediatr; 2009 Aug; 155(2):289-91. PubMed ID: 19619754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib-mesylate for all patients with hypereosinophilic syndrome?
    Musto P; Perla G; Minervini MM; Carella AM; Coco FL; Catalano G
    Leuk Res; 2004 Jul; 28(7):773-4. PubMed ID: 15158099
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful treatment with imatinib mesylate of hypereosinophilic syndrome (chronic eosinophilic leukemia) with myelofibrosis.
    Ishii Y; Ito Y; Kuriyama Y; Tauchi T; Ohyashiki K
    Leuk Res; 2004 May; 28 Suppl 1():S79-80. PubMed ID: 15036947
    [No Abstract]   [Full Text] [Related]  

  • 20. [Practical approach to hypereosinophilia].
    Roufosse F; Cogan E
    Rev Med Brux; 2008 Sep; 29(4):400-8. PubMed ID: 18949995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.